Anavex Life Sciences to Announce Fiscal 2022 First Quarter Financial Results on Wednesday, February 9, 2022

Rhea-AI Summary

Anavex Life Sciences Corp. (Nasdaq: AVXL) announced a conference call scheduled for February 9, 2022, to discuss financial results for the fiscal quarter ending December 31, 2021.

The call will cover the company's growth strategy, following a successful Phase 2a trial for its lead drug candidate ANAVEX^®2-73, which targets Alzheimer’s, Parkinson's, and Rett syndromes.

Management will also engage in a Q&A session, with further information available on their website.

Positive

• Successfully completed a Phase 2a clinical trial for ANAVEX®2-73 (blarcamesine) targeting Alzheimer's disease.
• Recent Phase 2 studies in Parkinson's dementia and Rett syndrome indicate strong clinical potential.

Negative

• None.

Webcast and Conference Call To be Held Wednesday, February 9, 2022, 4:30 pm ET

NEW YORK, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal quarter ended December 31, 2021 on Wednesday, February 9, 2022.

Management will host a conference call on Wednesday, February 9, 2022, at 4:30 pm ET to review financial results and provide an update on the execution of the Company’s growth and market access strategy. Following management’s remarks, there will be a question-and-answer session.

Webcast / Conference Call Information:

The live webcast of the conference call will be available on Anavex’s website at www.anavex.com.

The conference call can be also accessed by dialing +1 929 205 6099 for participants in the U.S. using the reference passcode 911357. A replay of the conference call will also be available on Anavex’s website for up to 30 days.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex’s lead drug candidate, ANAVEX^®2-73 (blarcamesine), successfully completed a Phase 2a clinical trial for Alzheimer’s disease and recently a Phase 2 proof-of-concept study in Parkinson’s disease dementia and a Phase 2 study in adult patients with Rett syndrome. ANAVEX^®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX^®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX^®2-73 for the treatment of Parkinson’s disease. ANAVEX^®3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX^®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook, Instagram and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:

Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com

Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com

FAQ

What are the financial results for Anavex Life Sciences Corp. for the quarter ended December 31, 2021?

Anavex will release its financial results on February 9, 2022.

When is the conference call for Anavex Life Sciences Corp. scheduled?

The conference call is scheduled for February 9, 2022, at 4:30 pm ET.

What is the focus of Anavex Life Sciences Corp.'s drug candidate ANAVEX®2-73?

ANAVEX®2-73 targets neurodegenerative diseases, specifically Alzheimer's, Parkinson's, and Rett syndromes.

How can I access the Anavex Life Sciences Corp. conference call?

The call can be accessed by dialing +1 929 205 6099 with passcode 911357 or via the webcast on Anavex’s website.